KR20240156394A - 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 - Google Patents

디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240156394A
KR20240156394A KR1020247032094A KR20247032094A KR20240156394A KR 20240156394 A KR20240156394 A KR 20240156394A KR 1020247032094 A KR1020247032094 A KR 1020247032094A KR 20247032094 A KR20247032094 A KR 20247032094A KR 20240156394 A KR20240156394 A KR 20240156394A
Authority
KR
South Korea
Prior art keywords
heterocycloalkyl
compound
alkyl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032094A
Other languages
English (en)
Korean (ko)
Inventor
홍푸 루
후아싱 유
샤오 딩
펭 렌
Original Assignee
인실리코 메디신 아이피 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인실리코 메디신 아이피 리미티드 filed Critical 인실리코 메디신 아이피 리미티드
Publication of KR20240156394A publication Critical patent/KR20240156394A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247032094A 2022-03-01 2023-03-01 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도 Pending KR20240156394A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2022078653 2022-03-01
CNPCT/CN2022/078653 2022-03-01
CN2022091497 2022-05-07
CNPCT/CN2022/091497 2022-05-07
CN2022127020 2022-10-24
CNPCT/CN2022/127020 2022-10-24
CNPCT/CN2023/071857 2023-01-12
CN2023071857 2023-01-12
PCT/CN2023/078948 WO2023165504A1 (en) 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20240156394A true KR20240156394A (ko) 2024-10-29

Family

ID=87883011

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032094A Pending KR20240156394A (ko) 2022-03-01 2023-03-01 디아실글리세롤 키나아제 (dgk) 알파 억제제 및 이의 용도

Country Status (12)

Country Link
US (2) US20240051958A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486741A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508971A (cg-RX-API-DMAC7.html)
KR (1) KR20240156394A (cg-RX-API-DMAC7.html)
CN (1) CN118871438A (cg-RX-API-DMAC7.html)
AR (1) AR128669A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023227010A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244501A1 (cg-RX-API-DMAC7.html)
IL (1) IL315015A (cg-RX-API-DMAC7.html)
MX (1) MX2024010648A (cg-RX-API-DMAC7.html)
TW (1) TW202342477A (cg-RX-API-DMAC7.html)
WO (1) WO2023165504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
TW200418829A (en) * 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
AU2004220176A1 (en) 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
WO2011075747A1 (en) 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
US10376504B2 (en) * 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
CN111406050B (zh) * 2018-01-17 2023-02-03 厦门宝太生物科技股份有限公司 吲哚胺2,3-双加氧酶抑制剂及其用途
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
MA56444A (fr) 2019-07-04 2022-05-11 Lead Pharma Holding Bv MODULATEURS DU RÉCEPTEUR ALPHA DES OESTROGÈNES (ERRalpha)
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
HRP20240237T1 (hr) 2019-10-18 2024-05-10 Lead Pharma Holding B.V. Modulatori receptora alfa (err-alfa) povezanih s estrogenom
US12478621B2 (en) * 2019-11-28 2025-11-25 Deutsches Krebsforschungszentrum Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
EP4065584A1 (en) 2019-11-28 2022-10-05 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
WO2021127554A1 (en) 2019-12-19 2021-06-24 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
MX2022007369A (es) 2019-12-23 2022-07-12 Bristol Myers Squibb Co Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t.
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
JP7677976B2 (ja) * 2019-12-23 2025-05-15 ブリストル-マイヤーズ スクイブ カンパニー T細胞アクティベーターとして有用な置換ヘテロアリール化合物
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
AU2021400725A1 (en) 2020-12-16 2023-08-03 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3228862A1 (en) 2021-08-03 2023-02-09 Beigene, Ltd. Pyrazolopyridinone compounds
WO2023165528A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486745A4 (en) 2022-03-01 2026-03-11 Insilico Medicine Ip Ltd Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses
WO2023165525A1 (en) 2022-03-01 2023-09-07 Insilico Medicine Ip Limited Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
JP2025510945A (ja) 2022-03-31 2025-04-15 インベンティスバイオ カンパニー リミテッド キナーゼ阻害剤、その製造方法および用途
WO2023184327A1 (en) 2022-03-31 2023-10-05 InventisBio Co., Ltd. Kinase inhibitors, preparation methods and uses thereof

Also Published As

Publication number Publication date
EP4486741A1 (en) 2025-01-08
IL315015A (en) 2024-10-01
WO2023165504A1 (en) 2023-09-07
EP4486741A4 (en) 2026-04-08
US12077538B2 (en) 2024-09-03
CA3244501A1 (en) 2023-09-07
US20240051958A1 (en) 2024-02-15
TW202342477A (zh) 2023-11-01
AU2023227010A1 (en) 2024-09-12
JP2025508971A (ja) 2025-04-10
US20240116935A1 (en) 2024-04-11
CN118871438A (zh) 2024-10-29
MX2024010648A (es) 2024-11-08
AR128669A1 (es) 2024-06-05

Similar Documents

Publication Publication Date Title
US12077538B2 (en) Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof
CN115448923B (zh) 嘧啶并环化合物及其制备方法和应用
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
US20250263418A1 (en) Modulators of tnf alpha activity and uses thereof
WO2023066283A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
WO2023165528A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4486745A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
JP7218431B2 (ja) 環状ジヌクレオチド類似体、その医薬組成物及び使用
CN115038707B (zh) 氮杂卓类稠环化合物及其医药用途
US20260008770A1 (en) Cbl-b inhibitors and methods of uses thereof
CN120535527A (zh) 一类含氮稠环类化合物、制备方法和用途
WO2024140799A1 (en) Inhibitors of kif18a and uses thereof
WO2025051110A1 (en) Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies
TW202434215A (zh) 螺環hpk1拮抗劑及其用途
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
AU2022262335A1 (en) Compounds as pd1/pd-l1 inhibitors and methods thereof
KR20230158659A (ko) Ctla-4 소분자 분해제 및 그 응용
HK40117800A (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EA049024B1 (ru) Ингибиторы parp1 на основе азетидина и пирролидина и их применение
HK1231051A1 (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
HK1231051A (en) Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000